Advancing a New Approach to Obesity Treatment Through Differentiated Oral GLP-1 Biology, Favorable Tolerability, & Muscle-Preserving Combination Potential
1:30 pm - Wednesday 9th December 2026
- Advancing clinical development, sharing Phase 1 safety and tolerability findings, and the transition into longer-duration Phase 1b studies evaluating ongoing efficacy
- Exploring a differentiated oral GLP-1 highlighting new preclinical and clinical insights into a novel allosteric GLP-1 mechanism, including its distinctive molecular profile and encouraging GI tolerability, with no meaningful nausea or vomiting observed to date
- Preserving muscle beyond weight loss Exploring the AMPK activator program in combination with GLP-1 therapy and its potential to support muscle preservation, alongside the next development milestones for both programs
